Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer

There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastases and 192...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2017-08, Vol.7 (1), p.9255-8, Article 9255
Hauptverfasser:	Xu, Li-Ming, Cheng, Chingyun, Kang, Minglei, Luo, Jing, Gong, Lin-Lin, Pang, Qing-Song, Wang, Jun, Yuan, Zhi-Yong, Zhao, Lu-Jun, Wang, Ping
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1059/485 692/4028/67/1612/2143 Adolescent Adult Aged Aged, 80 and over Chemotherapy Female Follow-Up Studies Humanities and Social Sciences Humans Lung cancer Lung Neoplasms - mortality Lung Neoplasms - pathology Lung Neoplasms - radiotherapy Male Metastasis Middle Aged multidisciplinary Neoplasm Metastasis Neoplasm Staging Prognosis Radiation therapy Science Science (multidisciplinary) Small cell lung carcinoma Small Cell Lung Carcinoma - mortality Small Cell Lung Carcinoma - pathology Small Cell Lung Carcinoma - radiotherapy Survival Survival Analysis Thorax Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastases and 192 (71.1%) had polymetastases, among which 51 oligometastatic patients (65.4%) and 93 polymetastatic patients (51.6%) received TRT. Propensity score matching (PSM) was utilized. The 2-year OS, progression free survival (PFS) and local control (LC) in oligometastatic and polymetastatic patients were 22.8% and 4.5% (p
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-017-09775-0